Gastrointestinal mucosal tissue (GI mucosa)

Gastrointestinal (GI) mucosal tissue is the innermost lining of the digestive tract, serving as the primary site for nutrient absorption and a critical barrier against luminal pathogens and toxins (StatPearls, 2023). It is composed of three distinct layers: the epithelium, the lamina propria, and the muscularis mucosae, each contributing to the tissue's complex physiological roles in secretion and immune surveillance (NIH, 2022). The tissue acts as a selective barrier, preventing the entry of pathogens and toxins while housing a significant portion of the body's immune system in the form of gut-associated lymphoid tissue (GALT) (PubMed, 2021). In various diseases, such as inflammatory bowel disease (IBD), peptic ulcers, and celiac disease, the integrity of the GI mucosa is compromised, leading to inflammation, malabsorption, and systemic complications (Mayo Clinic, 2023). While GI mucosal tissue is not a single molecular target, it contains numerous specific targets for drug therapy, including cytokine receptors, ion pumps, and cell adhesion molecules (Nature Reviews Gastroenterology & Hepatology, 2020). Therapeutic strategies often aim for mucosal healing, which is achieved through drugs like biologics, proton pump inhibitors, and aminosalicylates that modulate specific pathways within the tissue to restore its structure and function (Lancet Gastroenterology & Hepatology, 2022).

Other names

Gastrointestinal mucosaIntestinal mucosaGastric mucosaDigestive tract liningMucous membrane of the gastrointestinal tract

Drugs acting within the GI mucosa utilize various mechanisms, including the inhibition of pro-inflammatory cytokines (e.g., TNF-alpha), blockade of leukocyte trafficking (e.g., alpha-4 beta-7 integrin), suppression of gastric acid secretion (e.g., H+/K+ ATPase inhibition), and enhancement of mucosal protective factors (e.g., prostaglandin analogs).